Abstract
The central endocannabinoid system is a neuroactive lipid signalling system in the brain which acts to control neurotransmitter release. The expression patterns of this system throughout limbic regions of the brain ideally situate it to exert regulatory control over emotional behaviour, mood and stress responsivity. A growing body of evidence unequivocally demonstrates that deficits in endocannabinoid signalling may result in depressive and anxiogenic behavioural responses, while pharmacological augmentation of endocannabinoid signalling can produce both antidepressive and anxiolytic behavioural responses. The aim of this review is to summarize current knowledge of the role of the endocannabinoid system in the etiology and treatment of mood and anxiety disorders, such as depression, anxiety and post-traumatic stress disorder. Collectively, both clinical and preclinical data argue that cannabinoid receptor signalling may be a realistic target in the development of a novel class of agent for the pharmacotherapy of mood and anxiety disorders.
CNS & Neurological Disorders - Drug Targets
Title: The Endocannabinoid System and the Treatment of Mood and Anxiety Disorders
Volume: 8 Issue: 6
Author(s): Matthew N. Hill and Boris B. Gorzalka
Affiliation:
Abstract: The central endocannabinoid system is a neuroactive lipid signalling system in the brain which acts to control neurotransmitter release. The expression patterns of this system throughout limbic regions of the brain ideally situate it to exert regulatory control over emotional behaviour, mood and stress responsivity. A growing body of evidence unequivocally demonstrates that deficits in endocannabinoid signalling may result in depressive and anxiogenic behavioural responses, while pharmacological augmentation of endocannabinoid signalling can produce both antidepressive and anxiolytic behavioural responses. The aim of this review is to summarize current knowledge of the role of the endocannabinoid system in the etiology and treatment of mood and anxiety disorders, such as depression, anxiety and post-traumatic stress disorder. Collectively, both clinical and preclinical data argue that cannabinoid receptor signalling may be a realistic target in the development of a novel class of agent for the pharmacotherapy of mood and anxiety disorders.
Export Options
About this article
Cite this article as:
Hill N. Matthew and Gorzalka B. Boris, The Endocannabinoid System and the Treatment of Mood and Anxiety Disorders, CNS & Neurological Disorders - Drug Targets 2009; 8 (6) . https://dx.doi.org/10.2174/187152709789824624
DOI https://dx.doi.org/10.2174/187152709789824624 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
TRH/TRH-R1 Receptor Signaling in the Brain Medulla as a Pathway of Vagally Mediated Gut Responses During the Cephalic Phase
Current Pharmaceutical Design Tianeptine: An Antidepressant with Memory-Protective Properties
Current Neuropharmacology The GH/IGF-1 Axis in Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets The Potential Therapeutic Role of the HMGB1-TLR Pathway in Epilepsy
Current Drug Targets Modulatory Effects and Molecular Mechanisms of Olive Oil and Other Dietary Lipids in Breast Cancer
Current Pharmaceutical Design Liver-Brain Axis in Sporadic Alzheimer’s Disease: Role of Ten Signature Genes in a Mouse Model
CNS & Neurological Disorders - Drug Targets Proline-Rich Peptides: Multifunctional Bioactive Molecules as New Potential Therapeutic Drugs
Current Protein & Peptide Science Mediators of Low-Grade Chronic Inflammation in Polycystic Ovary Syndrome (PCOS)
Current Pharmaceutical Design Blood Pressure and Vascular Alterations with Growth in Childhood
Current Pharmaceutical Design Editorial [Hot Topic: New Antidepressant Drugs: Beyond Monoaminergic Mechanisms (Executive Editors: Cecilio Alamo and Francisco Lopez-Munoz)]
Current Pharmaceutical Design RNA Interference-Based Gene Silencing in Mice: The Development of a Novel Therapeutical Strategy
Current Pharmaceutical Design Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome
Current Pharmaceutical Design Development of Prolactin Receptor Antagonists: Same Goal, Different Ways
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Prevention and Treatment of Alzheimer Disease and Aging: Antioxidants
Mini-Reviews in Medicinal Chemistry Dissecting Cause and Effect in the Pathogenesis of Psychiatric Disorders: Genes, Environment and Behaviour
Current Molecular Medicine Glucocorticoid Receptor Interacting Co-regulators: Putative Candidates for Future Drug Targeting Therapy
Mini-Reviews in Medicinal Chemistry Transgenic Mouse Models of Parkinsons Disease and Huntingtons Disease
CNS & Neurological Disorders - Drug Targets Proinflammatory Activities of Leptin in Non-Autoimmune Conditions
Inflammation & Allergy - Drug Targets (Discontinued) The Effects of Maternally Administered Methadone, Buprenorphine and Naltrexone on Offspring: Review of Human and Animal Data
Current Neuropharmacology Towards Environmental Construct Validity in Animal Models of CNS Disorders: Optimizing Translation of Preclinical Studies
CNS & Neurological Disorders - Drug Targets